LOS ANGELES, Oct. 03, 2023 (GLOBE NEWSWIRE) -- NeuroSigma today announced approval of the Monarch eTNS System by Singapore’s Health Sciences Authority (HSA), the national body that regulates medical devices, therapeutics, and other healthcare products. The Monarch external Trigeminal Nerve Stimulation (eTNS) System is indicated for treatment of pediatric attention deficit hyperactivity disorder (ADHD) as a monotherapy for patients ages 7 through 12 years old who are not currently taking prescrip
Related Keywords
United States , California , Singapore , Los Angeles , Colin Kealey , C Thomas Paschall , Singapore Health Sciences Authority , Checkmate Capital Group , Health Sciences Authority , Trigeminal Nerve Stimulation , Neurosigma Singapore , Southeast Asia , George Clinical , Checkmate Capital , The Monarch , Regulatory Approval , Neurosigma , Fda Approval , Tns , Nnounced Approval ,
comparemela.com © 2020. All Rights Reserved.